• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neuronetics, Inc. - Common Stock (NQ:STIM)

    1.870 +0.060 (+3.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Neuronetics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
    New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
    New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
    First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment... 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
    Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
    New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
    New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
    Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
    Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
    NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
    Policy update increases access for millions covered by Evernorth Health Services 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
    Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
    Data selected for oral presentation reinforce previous findings on safety and efficacy 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
    Policy update increases access for millions covered by HCSC BlueCross BlueShield policies 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
    BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® Releases Software Upgrades to Elevate Patient Care
    Upgrades improve communication, streamline data management, and strengthen security 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
    NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
    Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
    New initiative aims to provide information and resources for teen mental health amidst rising public health concerns 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Aetna Policy Update Expands TMS Availability for Adolescents With Depression
    Coverage criteria consistent with recent FDA clearance for NeuroStar TMS 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
    NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
    Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® Launches Better Me Provider Program Nationwide
    The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
    Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
    Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
    The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
    Lack of early symptom improvement is not predictive of final responder status 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
    NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older 
    From Neuronetics
    Via GlobeNewswire
    News headline image
    Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
    From Neuronetics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.